Scientific Publications
View publications containing scientific information about MiniMed technologies.
The MiniMedTM 780G system has been robustly studied across broad populations, including people who are naive to pump therapy and belong to diverse age groups, varying ranges of starting therapy, and levels of glycemic control.1-3
This site will continue to be updated with the most current on-label publications.
2024
| First Author | Title | Authors | Pediatric (Y/N) | Epub Month | Publication Year |
|---|---|---|---|---|---|
| LaBlanche | 12-Month Real-Life Efficacy of the MiniMedTM 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study. | Lablanche S, Delagenière J, Jalbert M, Sonnet E, Benichou M, Arnold N, Spiteri A, Le Berre JP, Renard E, Chevalier N, Borot S, Bonnemaison E, Coffin C, Teissier MP, Benhamou PY, Borel JC, Penfornis A, Joubert M, Kessler L. | Adult | February | 2024 |
| Landau | A comparison of the usage of an open-source automated insulin delivery system and the MiniMedTM 780G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group | Landau Z, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, Jacobi-Polishook T, Ben Ari T, Abiri S, Haim A, Nir J, Rachmiel M, Pinhas-Hamiel O. | Pediatric | January | 2024 |
| Seget | Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study | Seget S, Chobot A, Tarasiewicz M, Bielawska A, Rusak E, Ochab A, Polanska J, Jarosz-Chobot P. | Pediatric | February | 2024 |
| Gardner | The cost-effectiveness of an advanced hybrid closed loop system compared to standard management of type 1 diabetes in a Singapore setting. | Gardner DSL, Lakkad M, Qiu Z, Inoue Y, Rama Chandran S, Wherry K. | Cost-utility analysis | March | 2024 |
| Roy | An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm | Roy A, Grosman B, Benedetti A, Engheta B, Miller D, Laron-Hirsh M, Cohen Y, Ré R, Edd SN, Vigersky R, Cohen O, Tirosh A. | Adult | March | 2024 |
| Halim | Advances in Automated Insulin Delivery with the MedtronicTM 780G: The Australian Experience | Halim B, Abraham MB, Manos G, Arrieta A, Dai Z, Vogrin S, Lu J, MacIsaac R, Ekinci EI, Davis EA, Jenkins A, Shin J, Vigersky RA, Jones TW, O'Neal D. | Pediatric/Adult | March | 2024 |
| LaBlanche | 12-Month Real-Life Efficacy of the MiniMedTM 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study. | Lablanche S, Delagenière J, Jalbert M, Sonnet E, Benichou M, Arnold N, Spiteri A, Le Berre JP, Renard E, Chevalier N, Borot S, Bonnemaison E, Coffin C, Teissier MP, Benhamou PY, Borel JC, Penfornis A, Joubert M, Kessler L. | Adult | February | 2024 |
| Atik-Altinok | Does MiniMedTM 780G insulin pump system affect energy and nutrient intake?: long-term follow-up study | Atik-Altinok Y, Mansuroglu Y, Demir G, Balki HG, Ozen S, Darcan S, Goksen D. | Pediatric/Adult | March | 2024 |
| Petrovski | Twelve-Month Follow-up from a Randomized Controlled Trial of Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMedTM 780G Advanced Hybrid Closed-Loop System | Petrovski G, Campbell J, Pasha M, Hussain K, Khalifa A, Umer F, Almajaly D, Hamdar M, Heuvel TVD, Edd SN. | Pediatric | March | 2024 |
| Choudhary | Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. | Choudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O. | Pediatric/Adult | March | 2024 |
| Akturk | Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems | Akturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O. | NA | March | 2024 |
| Grosman | A Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection Technology. | Grosman B, Roy A, Lintereur L, Turksoy K, Benedetti A, Cordero TL, Vigersky RA, McVean J, Rhinehart AS, Cohen O. | NA | March | 2024 |
| Vigersky | The Myth of MARD (Mean A bsolute R elative D ifference): Limitations of MARD in the Clinical Assessment of Continuous Glucose Monitoring Data | Vigersky RA, Shin J. | NA | March | 2024 |
| Garg | Development and Future of Automated Insulin Delivery (AID) Systems | Garg SK, McVean JJ. | NA | March | 2024 |
| Forlenza | Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems | Forlenza GP, Dai Z, Niu F, Shin JJ. | Pediatric/Adult | March | 2024 |
| Buckingham | Decreasing the Burden of Carbohydrate Counting and Meal Announcement with Automated Insulin Delivery, Meal Recognition, and Autocorrection Doses: A Case Study. | Buckingham BA, Bergenstal RM. | Pediatric Case Report | March | 2024 |
| Lingen | Removing Barriers, Bridging the Gap, and the Changing Role of the Health Care Professional with Automated Insulin Delivery Systems | Lingen K, Maahs D, Bellini N, Isaacs D. | NA | March | 2024 |
| Thrasher | Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States | Thrasher JR, Arrieta A, Niu F, Cameron KR, Cordero TL, Shin J, Rhinehart AS, Vigersky RA. | Pediatric/Adult | March | 2024 |
| O'Neal | Exercising Safely with the MiniMed™ 780G Automated Insulin Delivery System | O'Neal DN, Zaharieva DP, Morrison D, McCarthy O, Nørgaard K. | Adult | March | 2024 |
| Considine | Real-World Evidence of Automated Insulin Delivery System Use. | Considine EG, Sherr JL. | Narrative review. | March | 2024 |
| Boucsein | Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial | Boucsein A, Zhou Y, Haszard JJ, Jefferies CA, Wiltshire EJ, Styles SE, Crocket HR, Galland BC, Pasha M, Petrovski G, Paul RG, de Bock MI, Wheeler BJ. | NA | March | 2024 |
| Singh | Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes | Singh R, Imberg H, Ahmadi SS, Hallström S, Jendle J, Tengmark BO, Folino A, Marie E, Lind M. | Adult | March | 2024 |
| Cherubini | Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study | Cherubini V, Fargalli A, Arnaldi C, Bassi M, Bonfanti R, Patrizia Bracciolini G, Cardella F, Dal Bo S, Delvecchio M, Di Candia F, Franceschi R, Maria Galassi S, Gallo F, Graziani V, Iannilli A, Mameli C, Marigliano M, Minuto N, Monti S, Mozzillo E, Pascarella F, Predieri B, Rabbone I, Roppolo R, Schiaffini R, Tiberi V, Tinti D, Toni S, Scaramuzza A, Vestrucci B, Gesuita R. | Pediatric | March | 2024 |
| Gómez Medina | Characteristics Associated With Elevated Time Below Range in Elderly Patients With Type 1 Diabetes Using an Automated Insulin Delivery System | Gómez Medina AM, Parra Prieto DA, Henao Carrillo DC, Gómez CM, Muñoz Velandia OM, Caicedo S, Kerguelen Villadiego AL, Rodríguez Hortúa LM, Lucero Pantoja OD, Uribe Valencia M, García Guete MM, Robledo Gómez S, Rondón Sepúlveda M. | Adult | March | 2024 |
| Fernández | Health-related quality of life in children with type 1 diabetes and advanced hybrid closed-loop systems | Huidobro Fernández B, Hevia Meana V, Ablanedo Mingot M, Costa Romero M. | Pediatric | March | 2024 |
| Mesa | Impact of an advanced hybrid closed-loop system on glycemic control throughout the menstrual cycle in women with type 1 diabetes prone to hypoglycemia | Mesa A, Solà C, Vinagre I, Roca D, Granados M, Pueyo I, Cabré C, Conget I, Giménez M. | Adult | March | 2024 |
| Jalilova | The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes | Jalilova A, Pilan BŞ, Demir G, Özbaran B, Balkı HG, Arslan E, Köse SG, Özen S, Darcan Ş, Gökşen D. | Pediatric | March | 2024 |
| Eviz | Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single-centre real-world study | Eviz E, Killi NE, Karakus KE, Can E, Gokce T, Yesiltepe Mutlu G, Hatun S. | Pediatric | April | 2024 |
| Ng | Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes | Ng SM, Wright NP, Yardley D, Campbell F, Randell T, Trevelyan N, Ghatak A, Hindmarsh PC. | Pediatric England National Health Service RWE | April | 2024 |
| Al-Sofiani | Real-World Prospective Study of the Effectiveness and Safety of Automated Insulin Delivery Compared With Other Modalities of Type 1 Diabetes Treatment During Ramadan Intermittent Fasting | Al-Sofiani ME, Alharthi S, Albunyan S, Alzaman N, Klonoff DC, Alguwaihes A. | April | 2024 | |
| Christensen | Automated Insulin Delivery in Adults With Type 1 Diabetes and Suboptimal HbA1c During Prior Use of Insulin Pump and Continuous Glucose Monitoring: A Randomized Controlled Trial | Christensen MB, Ranjan AG, Rytter K, McCarthy OM, Schmidt S, Nørgaard K. | Adult | April | 2024 |
| Forlenza | Response to: MiniMed™ 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias-Response to Inaccurate Allegations | Forlenza GP, Sherr JL. | Response to Coment | April | 2024 |
| van den Heuvel | MiniMed™ 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias: Response to Inaccurate Allegations | van den Heuvel T, Castaneda J, Thijs I, Arrieta A, Lintereur L, Shin J, Cohen O. | Comment | April | 2024 |
| Gruber | Real-Life Achievements of MiniMed™ 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial | Gruber N, Wittenberg A, Brener A, Abiri S, Mazor-Aronovitch K, Yackobovitch-Gavan M, Averbuch S, Ben Ari T, Levek N, Levran N, Landau Z, Rachmiel M, Pinhas-Hamiel O, Lebenthal Y. | Pediatric | May | 2024 |
| Beato-Vibora | Beato-Víbora et al. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-World Setting. | Beato-Víbora PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mir S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C. | Pediatric/Adult | May | 2024 |
| Beato-Vibora | Response to Comment on Beato-Víbora et al. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. Diabetes Care 2024;47:216-224 | Beato-Víbora PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mira S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C. | NA | May | 2024 |
| Bahillo-Curieses | Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems. | Bahillo-Curieses P, Fernández Velasco P, Pérez-López P, Vidueira Martínez AM, Nieto de la Marca MO, Díaz-Soto G. | Pediatric/Adult | May | 2024 |
| Messer | Regarding Singh et al, "Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes" | Messer LH, Welsh JB, Habif S, Pinsker JE, Walker TC. | NA | June | 2024 |
| Passanisi | Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study | Passanisi S, Salzano G, Bombaci B, Minuto N, Bassi M, Bonfanti R, Scialabba F, Mozzillo E, Di Candia F, Monti S, Graziani V, Maffeis C, Piona CA, Arnaldi C, Tosini D, Felappi B, Roppolo R, Zanfardino A, Delvecchio M, Lo Presti D, Calzi E, Ripoli C, Franceschi R, Reinstadler P, Rabbone I, Maltoni G, Alibrandi A, Zucchini S, Marigliano M, Lombardo F; ISPED Diabetes Study Group Collaborators. | Pediatric | June | 2024 |
| Olid-Cárdenas | Real-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration Strategies in Children and Adolescents | Olid-Cárdenas MJ, Lendínez-Jurado A, Monroy-Rodríguez G, Gómez-Perea A, Cano-Ortiz A, Ariza-Jiménez AB, García-Ruiz A, Jiménez-Cuenca P, Picón-César MJ, Leiva-Gea I. | Pediatric | July | 2024 |
| Schiaffini | Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies | Schiaffini R, Lumaca A, Martino M, Rapini N, Deodati A, Amodeo ME, Ciampalini P, Matteoli MC, Pampanini V, Cianfarani S. | Pediatric | July | 2024 |
| Kessler | Advanced Hybrid Closed Loop Algorithm Use in Type 1 Diabetes: The French MiniMed™ Glycemic Control and Quality of Life Study | Laurence Kessler, Charles Thivolet,Alfred Penfornis,Didier Gouet,Christine Coffin,Myriam Moret,Sophie Borot,Saïd Bekka,Emmanuel Sonnet,Michael Joubert,Sandrine Lablanche,Geoffrey Burtin,Fabio Di Piazza,Tim van den Heuvel,Ohad Cohen | Pediatric/Adult | November 2024 | 2024 |
| Piona | Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes | Piona C, Passanisi S, Bombaci B, Marigliano M, Lombardo F, Mancioppi V, Morandi A, Maffeis C, Salzano G; ISPED Diabetes Study Group. | Pediatric | July | 2024 |
| Resmini | Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience | Resmini E, Zarra E, Dotti S, Rotondi G, Cornaghi AV, Madaschi S, Cimino E, Massari G, Pezzaioli LC, Buoso C, Sandri M, Girelli A. | NA | July | 2024 |
| Minsky | Simplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop System | Minsky N, Shalit R, Benedetti A, Laron-Hirsh M, Cohen O, Kurtz N, Roy A, Grosman B, Tirosh A. | NA | August | 2024 |
| Elbarbary | MiniMed™ 780G System Use in Type 1 Diabetes During Ramadan Intermittent Fasting: A Systematic Literature Review and Expert Recommendations | Elbarbary N, Alguwaihes A, Zarif H, Hassanein M, Deeb A, Petrovski G, Al Dahash R, Alamoudi R, Hussain S, Ibrahim M, Shaikh S, Zainudin SB, Chaar W, van den Heuvel T, Al-Sofiani ME. | NA | August | 2024 |
| Matejko | Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort | Matejko B, van den Heuvel T, Castaneda J, Arrieta A, Cyranka K, Cohen O, Małecki M, Klupa T. | NA | August | 2024 |
| van den Heuvel | Generating real-world evidence on diabetes technology using the CareLink Personal data management system | van den Heuvel T, Castañeda J, Arrieta A, Voelker B, Cohen O, Liu M, Diaz Garelli F, Shin J. | NA | September | 2024 |
| Nigi | 12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 Diabetes | Nigi L, Simon Batzibal MLA, Cataldo D, Dotta F. | Adult | September | 2024 |
| Gomez | Temporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical Trial | Gómez AM, Henao DC, Muñoz OM, Romero DM, León JDS, Jaramillo PE, Moscoso E, Parra Prieto DA, Robledo S, Jaramillo MG, Rondón Sepúlveda M. | Adult | September | 2024 |
| Boucsein | Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c | Boucsein A, Zhou Y, Michaels V, Haszard JJ, Jefferies C, Wiltshire E, Paul RG, Parry-Strong A, Pasha M, Petrovski G, de Bock MI, Wheeler BJ. | Pediatric/Adult | September | 2024 |
| Geraldine | Expert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensus. | Geraldine G, Alice R, Núria AC, Sima A, Virginie B, Vanessa B, Kerstin E, Francesca G, Audrey H, Amy J, Rea J, Anna SB, Paola C. | NA | October | 2024 |
| Dekker | Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care. | Dekker P, van den Heuvel T, Arrieta A, Castañeda J, Mul D, Veeze H, Cohen O, Aanstoot HJ. | Pediatric/Adult | October | 2024 |
| Gawrecki | Novel Protocol for the Use of Advanced Hybrid Closed-Loop System in Adolescents Engaged in Contact Sports | Gawrecki A, Chrzanowski J, Michalak A, Fendler W, Cohen O, Szadkowska A. | Pediatric | October | 2024 |
| Wong | Experiences of adolescents and young adults with type 1 diabetes and chronically elevated glucose levels following the transition from multiple daily injections to advanced hybrid closed-loop: A qualitative study. | Wong JY, Styles SE, Wiltshire EJ, de Bock MI, Boucsein A, Palmer OJ, Wheeler BJ. | Pediatric/Adult | October | 2024 |
| Nattero-Chávez | Comparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetes | Nattero-Chávez L, de La Calle E, Lecumberri-Pascual E, Bayona Cebada A, Ruiz Gracia T, Quintero Tobar A, Lorenzo Moñino M, Sánchez Rodríguez C, Izquierdo A, Escobar-Morreale HF, Luque-Ramírez M. | Adult | October | 2024 |
| Gargouri | Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed™ 780G according to patient characteristics | Gargouri I, Charfi H, Belabed W, Outenah C, Pochat A, Touimer M, Huynh P, Petit C, Lejeune M, Eroukhmanoff J, Ly Sall K, Penfornis A, Amadou C. | Adult (>16 years) | December | 2024 |
| Borella | Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systems | Borella ND, Ferramosca A, Castagna G, Ippolito S, Ceresoli S, Taverna A, Sonzogni B, Trevisan R, Lepore G. | Adult | November | 2024 |
| Lundemose | Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed™ 780G, an automated insulin delivery system? | Lundemose SB, McCarthy OM, Christensen MB, Laugesen C, Bracken RM, Holst JJ, Ranjan AG, Nørgaard K. | Adult | November | 2024 |
| Kogai | Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus | Kogai T, Sato J, Yasuda H, Ayame T, Ozaki A, Takagi E, Koshibu M, Nishida Y, Ikeda F, Watada H. | Adult | November | 2024 |
| Gargouri | Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed™ 780G according to patient characteristics | Gargouri I, Charfi H, Belabed W, Outenah C, Pochat A, Touimer M, Huynh P, Petit C, Lejeune M, Eroukhmanoff J, Ly Sall K, Penfornis A, Amadou C. | Pediatric/Adult | December | 2024 |
| Alguwaihes AM | The Use of MiniMed™ 780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study. | Alguwaihes AM, Alotaibi N, Alotaibi M, Masry N, Safarini S. | Pediatric/Adult | January | 2024 |
| Zhou | Predictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed™ 780G system. | Zhou Y, Boucsein A, Michaels VR, Gray MK, Jefferies C, Wiltshire E, Paul RG, Parry-Strong A, Pasha M, Petrovski G, de Bock MI, Wheeler BJ. | Pediatric/Adult | January | 2024 |
| Kiilavuori | Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system. | Kiilavuori M, Varimo T, Tuomaala AK, Pulkkinen MA. | Pediatric | January | 2024 |
| Abraham | Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial. | Abraham MB, Smith GJ, Dart J, Clarke A, Bebbington K, Fairchild JM, Ambler GR, Cameron FJ, Davis EA, Jones TW. | Pediatric | January | 2024 |
| Moser | The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). | Moser O, Zaharieva DP, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, Danne T, Davis EA, Dovč K, Forlenza GP, Gillard P, Hofer SE, Hovorka R, Jacobs PG, Mader JK, Mathieu C, Nørgaard K, Oliver NS, O'Neal DN, Pemberton J, Rabasa-Lhoret R, Sherr JL, Sourij H, Tauschmann M, Yardley JE, Riddell MC. | NA | February | 2024 |
| McVean | Hyperglycemia from Real World Dawn Phenomenon Is Nearly Eliminated with the MiniMed™ 780G System | Jennifer McVean, John Shin, Fang Niu, Franck Diaz-Garelli, Robert Vigersky | Pediatric/Adult | June | 2024 |
| Shin | Significant Reduction in Real-World Nighttime Burden with the MiniMed™ 780G System | John Shin, Zheng Dai, Naveen Mathew Nathan Sathiyanathan, Robert Vigersky, Jennifer McVean | Pediatric/Adult | June | 2024 |
| Kommareddi | Cost-Effectiveness of the MiniMed™ 780G System vs. Multiple Daily Injections (MDI) Used with the Dexcom G6 Continuous Glucose Monitoring (CGM) System | Mallika Kommareddi, Robert Vigersky | Adult | June | 2024 |
| Castaneda | Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed™ 780G System | Javier Castaneda, Arcelia Arrieta, Tim van den Heuvel, Tadej Battelino, Ohad Cohen | Pediatric/Adult | June | 2024 |
| Sehgal | Use of a decision support tool and quick start onboarding tool in individuals with type 1 diabetes using advanced automated insulin delivery: a single-arm multi-phase intervention study | Shekhar Sehgal, Martin De Bock, Benyamin Grosman, Jonathan Willman, Natalie Kurtz, Vanessa Guzman, Andrea Benedetti, Anirban Roy, Kamuran Turksoy, Magaly Juarez, Shirley Jones, Crla Frewen, Antony Watson, Barry Taylor, Benjamin Wheeler | Adult | August | 2024 |
| Pollakova | Advanced hybrid closed loop (artificial pancreas) and carbohydrate count in type 1 diabetes | Daniela Pollakova, Angelo Lauria Pantano, Claudio Tubuli, Ugo Di Folco, Maria Rosaria Nardone | Adult | June | 2024 |
| Benedetti | A Retrospective CGM-Driven Missed Meal Bolus Detection Tool | Andrea Benedetti, Arthur Mikhno, Anirban Roy, John Shin | Pediatric/Adult | June | 2024 |
| Yang | Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis | Qin Yangm BBaoqi Zeng, Jiayi Hao, Qingping Yang, Feng Sun | June | 2024 | |
| Passanisi | Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed™ 780G in Children, Adolescents and Young Adults: A Systematic Review | Stefano Passanisi, Fortunato Lombardo, Chiara Mameli, Bruno Bombaci, Maddalena Macedoni, Gianvincenzo Zuccotti, Klemen Dovc, Tadej Battelino, Giuseppina Salzano, Maurizio Delvecchio | December | 2024 | |
| Al-Sofiani | The MiniMed™ 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan | Mohammed E. Al-Sofiani MD, Goran Petrovski MD, Abdulrahman Al Shaikh MD, Abdullah Alguwaihes MD, Mohammad Al Harbi MD, Dabia Al Mohannadi MD, Alero Adjene MD, Abdulmoeen Alagha MD, Sareea Al Remeithi MD, Naji Alamuddin MD, Arcelia Arrieta MSc, Javier Castañeda MSc, Wael Chaar PharmD, Tim van den Heuvel PhD, Ohad CohenMD | Adult | December | 2024 |
| Elhenawy | Performance of the MiniMed™ 780G system on mitigating menstrual cycle-dependent glycaemic variability | Yasmine Ibrahim Elhenawy 1, Mohamed S Abdel Kader 2, Rasha A Thabet | Pediatric | September | 2024 |
| Di Molfetta | Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis | Sergio Di Molfetta 1, Ludovico Di Gioia 1, Irene Caruso 1, Angelo Cignarelli 1, Suetonia C Green 2, Patrizia Natale 3 4 5, Giovanni F M Strippoli 3 4, Gian Pio Sorice 1, Sebastio Perrini 1, Annalisa Natalicchio 1, Luigi Laviola 1, Francesco Giorgino 1 | Pediatric/Adult | September | 2024 |
| Gallen | Expert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensus | Geraldine Gallen 1, Alice Rosso 2, Núria Alonso-Carril 3, Sima Arbeli 4, Virginie Bahon 5, Vanessa Brown 6, Kerstin Endlich 7, Francesca Gulotta 8, Audrey Hansart 9, Amy Jolley 10, Rea Jussila 11, Anna Stefanowicz-Bielska 12 13, Paola Cardano | October | 2024 | |
| Gallen | Correction: Expert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensus | Geraldine Gallen 1, Alice Rosso 2, Núria Alonso-Carril 3, Sima Arbeli 4, Virginie Bahon 5, Vanessa Brown 6, Kerstin Endlich 7, Francesca Gulotta 8, Audrey Hansart 9, Amy Jolley 10, Rea Jussila 11, Anna Stefanowicz-Bielska 12 13, Paola Cardano | December | 2024 | |
| Henry | Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics | Zoé Henry 1, Sylvie Villar Fimbel 1, Nathalie Bendelac 1 2, Kevin Perge 2, Charles Thivolet | Pediatric/Adult | October | 2024 |
| Karakus | Insulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days' Real-World Data of Children in Two Different Age Groups | Kağan Ege Karakuş 1, Gül Yeşiltepe Mutlu 1 2, Tuğba Gökçe 2, Elif Eviz 2, Ecem Can 2, Serra Muradoğlu 2, Şükrü Hatun | June | 2024 | |
| Lepore | Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy | Giuseppe Lepore 1, Nicolò Diego Borella 1, Giona Castagna 1 2, Silvia Ippolito 1, Silvia Bonfadini 1, Anna Corsi 1, Cristiana Scaranna 1, Alessandro Roberto Dodesini 1, Rosalia Bellante 1, Roberto Trevisan | Adult | January | 2024 |
2023
2022
2021
| First Author | Title | Authors | Pediatric (Y/N) | Epub Month | Publication Year |
|---|---|---|---|---|---|
| Bergenstal | A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. | Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M; FLAIR Study Group. | Pediatric/Adult | January | 2021 |
| Collyns | Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. | Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, Hewapathirana NM, Jones SD, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, Wheeler BJ, de Bock MI. | Pediatric/Adult | April | 2021 |
| Rizzi | Advanced hybrid closed-loop system: first successful clinical case after total pancreatectomy. | Rizzi A, Tartaglione L, Di Leo M, Alfieri S, Pitocco D. | Adult | April | 2021 |
| Wheeler | Improved technology satisfaction and sleep quality with Medtronic MiniMed™ Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial. | Wheeler BJ, Collyns OJ, Meier RA, Betts ZL, Frampton C, Frewen CM, Galland B, Hewapathirana NM, Jones SD, Chan DSH, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, de Bock MI. | Pediatric/Adult | January | 2021 |
| Beato-Vibora | Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting. | Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ. | Adult | August | 2021 |
| Petrovski | Virtual training on advanced hybrid closed-loop system MiniMed 780G in a teenager with type 1 diabetes previously treated with multiple daily injections: A case report. | Petrovski G, Campbell J, Almajali D, Al Khalaf F, Hussain K. | Pediatric | August | 2021 |
| Piccini | Type 1 diabetes technology management traps in a pediatric patient: not all that glitters is gold. | Piccini B, Casalini E, Macucci C, Toni S. | Pediatric | January | 2021 |
| Lee | Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. | Lee MH, Paldus B, Vogrin S, Morrison D, Zaharieva DP, Lu J, Jones HM, Netzer E, Robinson L, Grosman B, Roy A, Kurtz N, Ward GM, MacIsaac RJ, Jenkins AJ, O'Neal DN. | Adult | August | 2021 |
| Beato-Vibora | Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes. | Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ. | Pediatric/Adult | September | 2021 |
| Da Silva | Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4'120 Users. | Da Silva J, Lepore G, Battelino T, Arrieta A, Castañeda J, Grosman B, Shin J, Cohen O. | adult | February | 2021 |
| Hood | Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. | Hood KK, Laffel LM, Danne T, Nimri R, Weinzimer SA, Sibayan J, Bailey RJ, Schatz D, Bratina N, Bello R, Punel A, Calhoun P, Beck RW, Bergenstal RM, Phillip M. | Pediatric/Adult | October | 2021 |
| Carlson | Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. | Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky | Pediatric/Adult | March | 2021 |
| Jendle | The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. | Jendle J, Buompensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O. | Mean age >45 y ped/adult | November | 2021 |
| Lambadiari | Cost-effectiveness analysis of an Advanced Hybrid Closed Loop insulin delivery system in people with type 1 diabetes in Greece. | Lambadiari V, Ozdemir Saltik AZ, de Portu S, Buompensiere MI, Kountouri A, Korakas E, Sharland H, Cohen O. | Mean age 33.8 y ped/adult | May | 2021 |
| Bassi | A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes | Bassi M, Teliti M, Lezzi M, Iosca A, Strati MF, Carmisciano L, d'Annunzio G, Minuto N, Maggi D. | Adults/Pediatric | January | 2021 |
| McVean | MiniMed™ 780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy | McVean J, Miller J. | -- | June | 2021 |
2020
| First Author | Title | Authors | Pediatric (Y/N) | Epub Month | Publication Year |
|---|---|---|---|---|---|
| Nimri | Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. | Nimri R, Grosman B, Roy A, Nir J, Fisch Shvalb N, Kurtz N, Loewenthal N, Gillon-Keren M, Muller I, Atlas E, Phillip M. | April | 2020 |
2019
| First Author | Title | Authors | Pediatric (Y/N) | Epub Month | Publication Year |
|---|---|---|---|---|---|
| Lee | Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study. | Lee MH, Vogrin S, Paldus B, Jones HM, Obeyesekere V, Sims C, Wyatt SA, Ward GM, McAuley SA, MacIsaac RJ, Krishnamurthy B, Sundararajan V, Jenkins AJ, O'Neal DN. | September | 2019 | |
| Paldus | Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. | Paldus B, Lee MH, Jones HM, McAuley SA, Horsburgh JC, Roem KL, Ward GM, MacIsaac RJ, Cohen N, Colman PG, Jenkins AJ, O'Neal DN. | January | 2019 |
2018
| First Author | Title | Authors | Pediatric (Y/N) | Epub Month | Publication Year |
|---|---|---|---|---|---|
| de Bock | Performance of Medtronic Hybrid Closed-Loop Iterations: Results from a Randomized Trial in Adolescents with Type 1 Diabetes. | de Bock M, Dart J, Hancock M, Smith G, Davis EA, Jones TW. | Mean age 15 | October | 2018 |
1. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714
2. Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; https://doi.org/10.1016/S2213-8587(22)00245-5
3. MatejkoB. et al, Diabetes Care. 2022; https://doi.org/10.2337/dc22-0470
Important Safety Information: MiniMed FlexTM system with SmartGuardTM technology with Simplera SyncTM sensor
The MiniMed FlexTM system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed FlexTM system includes SmartGuardTM technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera SyncTM sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera SyncTM sensor is not intended to be used directly to make therapy adjustments while the MiniMed FlexTM system is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera SyncTM sensor. The Simplera SyncTM sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera SyncTM sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed FlexTM System consists of the following devices: MiniMed FlexTM Insulin Pump and the Simplera SyncTM sensor. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuardTM feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuardTM feature.
WARNING: Do not use the MiniMed FlexTM system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed FlexTM system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuardTM feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed FlexTM system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including user guides and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, see https://bit.ly/MiniMedRisks.